Who are Azithromycin on Day 1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): azithromycin (AZ), Dalacin C, Intravenous Clarithromycin, Zmax, Altabax (R), P.O roxithromycin 150 mg*2/d for 7 days.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azithromycin-on-day-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Azithromycin on Day 1 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azithromycin on Day 1 (Azithromycin on Day 1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Infectious Disease.

phase 3 Macrolide antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Azithromycin on Day 1 (Azithromycin on Day 1) — Lihir Medical Centre. Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and halting bacterial growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Azithromycin on Day 1 TARGET	Azithromycin on Day 1	Lihir Medical Centre	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit
azithromycin (AZ)	azithromycin (AZ)	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Dalacin C	Dalacin C	Oral and Maxillofacial Surgery Clinic, Poland	marketed	Lincosamide antibiotic	Bacterial 50S ribosomal subunit
Intravenous Clarithromycin	Intravenous Clarithromycin	University of Athens	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Zmax	Zmax	Pfizer	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Altabax (R)	Altabax (R)	St. Luke's-Roosevelt Hospital Center	marketed	Pleuromutilin antibiotic	Bacterial 50S ribosomal subunit
*P.O roxithromycin 150 mg2/d for 7 days**	P.O roxithromycin 150 mg*2/d for 7 days	Western Galilee Hospital-Nahariya	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

Pfizer · 6 drugs in this class
Grünenthal GmbH · 4 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
University of Taubate · 2 drugs in this class
Lihir Medical Centre · 2 drugs in this class
Thomas Jefferson University · 2 drugs in this class
Copenhagen Studies on Asthma in Childhood · 1 drug in this class
Ain Shams Maternity Hospital · 1 drug in this class
Celltrion · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Azithromycin on Day 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/azithromycin-on-day-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing